PD-010REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

Introduction: REVERCE demonstrated longer overall survival (OS) with the therapeutic sequence of regorafenib (R) followed by cetuximab (C) ± irinotecan (R-C arm) compared with that of C ± irinotecan followed by R (C-R arm) for patients (pts) with pretreated metastatic colorectal cancer (mCRC; median OS 17.4 vs. 11.6 months, HR 0.61; Shitara K, et al. GI Symposium 2018). Here we report quality of life (QOL) analysis.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research